BRAF and malignant colon neoplasm: Recently, Russo and colleagues [91] provided evidence suggesting that colon cancer patients undergoing targeted therapy by inhibitors of EGFR (epidermal growth factor receptor) and/or BRAF (serine/threonine-protein kinase B-Raf) might also become resistant to these treatments by a similar mechanism.